England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet syndrome ...

Biogen has refueled its R ... Existing treatments for Dravet include Jazz Pharmaceuticals’ Epidiolex and UCB’s Fintepla, but none of the approved products address the underlying genetic ...

Biogen has received an option to license rights to certain future antisense oligonucleotide products targeting ... originally created and published by Pharmaceutical Technology, a GlobalData ...

Learn more about whether Ionis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number ...

TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...

Biogen Inc. (NASDAQ ... see in 2024 that the revenue from our launch products really offset the more than offsets the decline in our multiple sclerosis product revenue… It meant that really our core ...

The patents cover sales of Biogen products for MS that are covered by a Forward Pharma patent and have dimethyl fumarate as an active pharmaceutical ingredient. The two companies say they intend ...

This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and ...

The global gene therapy market is projected to grow from $8.85 billion in 2024 to $36.55 billion by 2032, at a CAGR of 19.4%.